[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"keloids\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:keloids":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,64,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100647058","scar-gel-product-family-clinical-investigation-100647058",false,"NCT07684573","Scar Gel Product Family Clinical Investigation","PMCF Investigation to Compare the Clinical Performance\u002FBenefit of Dermatix With Dermatix Ultra","Inclusion Criteria:\n\n* Patients aged \\>3 years.\n* Patients with keloids and hypertrophic scars (such as those resulting from general surgical procedures, trauma wounds, and burns), i.e., older scars.\n* Patients at risk of developing keloids and hypertrophic scars, i.e., recent scars.\n\nExclusion Criteria:\n\n* Patients with unhealed and\u002For open wounds.\n* Patients with allergies to any of the ingredients.\n* Pregnant or breastfeeding women.\n* Patients using other topical skin treatments on\u002Faround the scar area.","ALL","3 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","The purpose of this PMCF investigation is to determine whether there are differences between the two formulations (Dermatix and Dermatix Ultra) in improving keloid and hypertrophic scars clinical symptoms and in the overall scar perception (including scar appearance and treatment perception).\n\nThis PMCF investigation has been designed to address the conclusions of the latest CER \\[PDPROJ-4-CE-R\\] and the objectives. It has been chosen as an appropriate activity as it enables the collection of device-specific data on both device formulations and on the entire intended population. Moreover, the design of the PMCF investigation (single-center, parallel, open-label, two-arm, randomized controlled study) enables the direct comparison of the clinical performance\u002Fbenefit between the two formulations.",[24,25],"Hypertrophic Scars","Keloids","NOT_YET_RECRUITING","2026-06-29",{"date":29,"type":30},"2026-07-06","ACTUAL",{"date":32,"type":20},"2026-07",{"date":34,"type":20},"2026-12",{"name":36,"class":37},"Hanson Medical, Inc.","INDUSTRY",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100646955","keloid-pathogenesis-and-fibroblast-activation-study-100646955","NCT07682636","Keloid Pathogenesis And Fibroblast Activation Study","Mechanisms Of Keloid Fibroblast Activation And Potential Therapeutic Targets: A Tissue-Based Translational Study","KPS","Inclusion Criteria:\n\n* Clinically diagnosed with keloid.\n* Age 18 years or older.\n* Scheduled to undergo surgical treatment at the study hospital.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Severe systemic disease.\n* History of neurologic disease, alcoholism, postherpetic neuralgia, HIV infection, hypothyroidism, diabetes mellitus, or prior cancer chemotherapy.\n* Other skin diseases within 5 cm of the keloid lesion, such as eczema.\n* Systemic treatment within 7 days before enrollment or keloid-specific treatment within 6 weeks before enrollment, including intralesional corticosteroid injection, cryotherapy, topical medication, or silicone gel sheeting.\n* Hormone or immunosuppressive therapy within 3 months before enrollment.\n* Pregnancy or breastfeeding.\n* Considered unsuitable for participation by the investigator.\n* Refusal to participate in the study.",true,"18 Years",{"count":49,"type":20},20,"Keloids are benign fibroproliferative skin disorders characterized by excessive fibroblast activation and extracellular matrix deposition. The molecular mechanisms underlying keloid formation remain incompletely understood. This prospective observational study aims to investigate the biological characteristics of keloid tissue by comparing surgically resected keloid specimens with adjacent normal skin obtained from the same patients. Histological and molecular analyses, including histopathology, polymerase chain reaction (PCR), Western blotting, and related laboratory assays, will be performed to identify signaling pathways and key regulatory factors associated with fibroblast activation. The findings may improve the understanding of keloid pathogenesis and identify potential therapeutic targets for future treatment.",[25,52],"Fibroblast","RECRUITING","2026-06-28",{"date":29,"type":30},{"date":57,"type":30},"2025-05-10",{"date":59,"type":20},"2028-05-30",{"name":61,"class":62},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","OTHER",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":63},"100633774","early-phase-1-comparison-of-effectiveness-of-intralesional-injectioms-of-5-flourouracil-alone-verses-its-cpmbination-with-cryotherapy-in-the-treatment-of-keloids-100633774","NCT07531056","Comparison Of Effectiveness Of Intralesional Injectioms Of 5 Flourouracil Alone Verses Its Cpmbination With Cryotherapy In The Treatment Of Keloids","A Randomized Controlled Trial Comparing The Effectiveness And Safety Of iIntralesional 5 Flourouracil Monotherapy Verses 5 Flourouracil Combined With Cryotherapy; In The Treatment Of Keloid Scars","Inclusion Criteria:\n\n* Patients willing to participate in the study\n* Patients of age group of 18 -50 years.\n* Patients having symptomatic keloids i.e., having pain, pruritus, restriction of movement, scar tension or disfigurement.\n\nExclusion Criteria\n\n:• Pregnant women or lactating women\n\n* Patients with history of hepatic, renal, cardiac diseases or chronic diarrhea.\n* Patients on immunosuppressant medications due to other diseases\n* Patients having myelosuppression checked by CBC.\n* Patient taking warfarin.\n* Patients with history of hypersensitivity to 5FU.","50 Years",{"count":73,"type":20},88,"INTERVENTIONAL",[76],"EARLY_PHASE1","The goal of this clinical trial is to learn how well intralesional 5 fluorouracil with cryotherapy works to treat keloids as compared to intralesional 5 fluorouracil alone on keloids. It will also learn about the safety of both these treatments. The main questions it aims to answer are:\n\n* What well does cryotherapy followed by intralesional 5 fluorouracil (5FU) work to treat keloids as compared to 5 fluorouracil (5FU) alone?\n* What is participant's satisfaction when treated with cryotherapy followed by intralesional 5 fluorouracil (5FU) as compared to 5 fluorouracil (5FU) alone?\n* What skin problems do participants have when treated with cryotherapy followed by intralesional 5 fluorouracil (5FU) and 5 fluorouracil (5FU) alone? Researchers will compare cryotherapy followed by intralesional 5 fluorouracil (5FU) with 5 fluorouracil (5FU) alone to see how well both work.\n\nParticipants will be divided into two groups:\n\nFor Group A: Cryotherapy will be done at lesion site followed by intralesional 5FU every 3 weekly.\n\nFor Group B: Intralesional 5FU will be given at lesion site every 3 weekly. Keloids will be assessed at the start of trial and then after 12 weeks of treatment.",[25],[25,80,81],"Intralesional injectioms","5-FU","2026-04-21",{"date":84,"type":30},"2026-04-24",{"date":86,"type":30},"2025-12-22",{"date":88,"type":20},"2026-09-20",{"name":90,"class":62},"Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100624735","a-prospective-observational-clinical-study-on-exploring-the-value-of-surgical-excision-combined-with-32p-application-in-the-treatment-of-keloids-and-the-factors-affecting-the-prognosis-of-combined-therapy-100624735","NCT07413497","A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in the Treatment of Keloids and the Factors Affecting the Prognosis of Combined Therapy","Inclusion Criteria:\n\n1. Histological biopsy confirms the patient has keloids. Pathological diagnostic criteria include: 1. Proliferating fibroblasts: A large number of proliferating fibroblasts are usually detected in keloid tissue. 2. Disordered arrangement of collagen fibers: Collagen fibers in normal scars are generally arranged in an orderly manner, while in keloids, they are disorganized and present as thick bundles. 3. Scar tissue extending beyond the original wound boundaries: Keloid tissue often spreads beyond the scope of the initial trauma.\n2. Patients with keloids ≥3 mm in thickness and within 1 week after surgical excision.\n3. Patients have at least one measurable lesion as defined by the Vancouver Scar Scale (VSS) criteria.\n4. Patients have no other skin disorders similar to keloids.\n5. Patients are capable of understanding and signing the informed consent form.\n6. Patients are willing and able to comply with scheduled visits, treatment plans, laboratory tests, follow-up appointments, and other study procedures.\n\nExclusion Criteria:\n\n1. Difficulty in accurately assessing the patient's lesions.\n2. Patients who do not meet the indications for local excision or have received superficial radiotherapy after surgery.\n3. Dementia, intellectual impairment, or any mental illness that hinders the understanding of the informed consent form.\n4. Patients deemed inappropriate to participate in this clinical study by the investigator.\n5. Patients from whom pathological specimens cannot be obtained, or those who die or are lost to follow-up.\n6. Patients with recurrent keloids following previous treatment.\n7. Pregnant female patients. -",{"count":98,"type":20},401,"Keloids are non-cancerous (benign) growths on the skin. They form after an injury, when the skin makes too much connective tissue that thickens and hardens.\n\nThese keloids cause big problems for people. They grow uncontrollably on their own, itch, hurt, and look bad. This is especially true if they're on visible areas like the head or neck-they harm both a person's physical comfort and mental well-being.\n\n32P application is a popular treatment for keloids. It's simple, easy to use, quick, and doesn't have many limits on where or when it can be used. Besides keloids, it also works for surface skin issues like hemangiomas.\n\nHere's how 32P works: When it breaks down (decays), it releases beta rays. These rays create a local effect that changes the shape and function of the affected tissue. Blood vessel cells in the area swell, get inflamed, and shrink, eventually blocking the blood vessels. Beta rays also stop two key things from growing too much: fibroblasts (cells that make connective tissue) and new blood vessels. This is how the treatment works-with very low chances of the keloid coming back and few side effects.\n\nFor these reasons, we think combining surgery with 32P application is an effective way to treat keloids. Its success rate is similar to, or even better than, surgery combined with low-dose radiation. Also, two factors matter a lot for how well the treatment works long-term: when 32P application is started, and the dose used.",[25,101],"Keloids Scars",[103,104,105,106,107],"32P","keloids","32P application","nuclide application therapy","nuclide therapy","2026-02-09",{"date":110,"type":30},"2026-02-17",{"date":112,"type":20},"2026-06-01",{"date":114,"type":20},"2030-06-01",{"name":116,"class":62},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"]